3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
2
Recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Conditions
Carcinoma, Basal Cell
2
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Cisplatin
270
Oxaliplatin
195
Carboplatin
191
Capecitabine
184
Docetaxel
178
apatinib
164
Paclitaxel
163
Bevacizumab
159
Gemcitabine
156
Radiotherapy
147
camrelizumab
146
Fluorouracil
144
Cyclophosphamide
126
Irinotecan
120
Drug Therapy
119
sintilimab
108
Etoposide
99
anlotinib
90
S 1 (combination)
89
Leucovorin
86
pembrolizumab
85
toripalimab
78
Pemetrexed
78
Doxorubicin
77
tislelizumab
76
Dexamethasone
71
Trastuzumab
65
Neoadjuvant Therapy
65
Rituximab
62
Cetuximab
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Unknown
×
daromun
×
Clear all
NCT04362722
2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2
Unknown
40 enrolled
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled